Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.

NCT06786299 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.

NCT NCT06786299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06786299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.
Lead sponsor
First Affiliated Hospital of Zhejiang University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 10, 2025
Completion date
December 31, 2026
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory acute myeloid leukemia(aml)